What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Enzyme
His primary areas of investigation include Internal medicine, Endocrinology, Diabetes mellitus, Diabetic nephropathy and Nephropathy.
His study in Kidney, Kidney disease, Albuminuria, Renal function and Oxidative stress are all subfields of Internal medicine.
His Albuminuria research integrates issues from Creatinine, Nephrology and Urology.
His research investigates the connection between Diabetes mellitus and topics such as Surgery that intersect with issues in Cardiology.
His research integrates issues of Glomerulosclerosis and Protein kinase C in his study of Diabetic nephropathy.
His studies deal with areas such as Randomized controlled trial, Blood pressure and Insulin resistance as well as Type 2 diabetes.
His most cited work include:
- EFFECTS OF LOSARTAN ON RENAL AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES AND NEPHROPATHY (5734 citations)
- Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. (5527 citations)
- Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index (2348 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Endocrinology, Diabetes mellitus, Diabetic nephropathy and Nephropathy.
Many of his studies involve connections with topics such as Type 2 diabetes and Internal medicine.
His research combines Receptor and Endocrinology.
His research in Diabetes mellitus intersects with topics in Cardiology, Disease, Blood pressure and Pharmacology.
His Renal function research is multidisciplinary, relying on both Creatinine and Urology.
His research in Glycation is mostly concerned with RAGE.
He most often published in these fields:
- Internal medicine (42.32%)
- Endocrinology (34.22%)
- Diabetes mellitus (26.18%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (42.32%)
- Diabetes mellitus (26.18%)
- Microbiology (4.14%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Diabetes mellitus, Microbiology, Inflammasome and Endocrinology are his primary areas of study.
His Internal medicine study frequently links to other fields, such as Type 2 diabetes.
His biological study spans a wide range of topics, including Clinical trial and Hazard ratio.
His research in Diabetes mellitus tackles topics such as Disease which are related to areas like Diabetic kidney.
His Endocrinology research focuses on Glomerulosclerosis and NADPH oxidase.
His work deals with themes such as Vancomycin, Antimicrobial and Bacteria, which intersect with Antibiotics.
Between 2016 and 2021, his most popular works were:
- Clonal hematopoiesis associated with Tet2 deficiency accelerates atherosclerosis development in mice (442 citations)
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. (423 citations)
- Emerging pathogenic links between microbiota and the gut-lung axis (381 citations)
In his most recent research, the most cited papers focused on:
- Gene
- Internal medicine
- Enzyme
The scientist’s investigation covers issues in Internal medicine, Diabetes mellitus, Inflammasome, Inflammation and Endocrinology.
His studies in Internal medicine integrate themes in fields like Type 2 diabetes and Linagliptin.
Mark E. Cooper has included themes like Cardiology, Vascular disease and Hazard ratio in his Type 2 diabetes study.
His Diabetes mellitus study combines topics from a wide range of disciplines, such as Disease, Pharmacology and Bioinformatics.
His Inflammasome research is multidisciplinary, incorporating elements of Neuroinflammation and Pathogenesis.
His Endocrinology study frequently draws parallels with other fields, such as Fibrosis.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
